Agents that modulate peritoneal membrane structure and function

Peritoneal Dialysis International

Volumn 27, Issue 1, 2007, Pages 16-30

  Diaz Buxo, Jose A ^a   Gotloib, Lazaro ^b  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b HAEMEK MEDICAL CENTER   (Israel)

Author keywords

Peritoneal dialysis solutions; Peritoneal membrane protection; Peritoneal membrane transport; Peritoneal solution additives

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMBROXOL; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HYALURONIC ACID; INDOMETACIN; ISOPRENALINE; LOW MOLECULAR WEIGHT HEPARIN; NICARDIPINE; NITROPRUSSIDE SODIUM; PAPAVERINE; PERITONEAL DIALYSIS FLUID; PHOSPHATIDYLCHOLINE; PLACEBO; PYRUVIC ACID; SCATTER FACTOR; SCAVENGER; SODIUM SULFITE; THIOCTIC ACID; UNINDEXED DRUG; VASODILATOR AGENT; ANTICOAGULANT AGENT; DIALYSIS FLUID; LAXATIVE; SODIUM SULFATE; SULFATE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANURIA; AUTOTRANSPLANTATION; BIOCOMPATIBILITY; CELL TRANSPLANTATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; GENE THERAPY; HUMAN; INFLAMMATION; LONG TERM CARE; LOW DRUG DOSE; MEMBRANE STRUCTURE; MEMBRANE TRANSPORT; MESOTHELIUM CELL; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PERITONEUM; PH; PRIORITY JOURNAL; REVIEW; WATER TRANSPORT; ANIMAL; ARTIFICIAL MEMBRANE; CHRONIC KIDNEY FAILURE; INSTRUMENTATION;

ANIMALS; ANTICOAGULANTS; CATHARTICS; DIALYSIS SOLUTIONS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; PERITONEAL DIALYSIS; SULFATES;

EID: 33947099383     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080702700105     Document Type: Review

References (121)

1. Bazargani F, Albrektsson A, Yahyapour N, Braide M. Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation. Perit Dial Int 2005; 25:394-404.
2. Jonasson P, Braide M. Acute in vivo toxicity of heat-sterilized glucose peritoneal dialysis fluids to rat peritoneal macrophages. Perit Dial Int 1998; 18:376-81.
3. Norrby K. Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis 1993; 23(Suppl 1):141-9.
4. Wang T, Heimburger O, Qureshi AR, Waniewski J, Bergstrom J, Lindholm B. Physiological saline is not a biocompatible peritoneal dialysis solution. Int J Artif Organs 1999; 22:88-93.
5. Breborowicz A, Wieczorowska K, Martis L, Oreopoulos DG. Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats. Nephron 1994; 67:346-50.
6. Gaggiotti E, Arduini A, Bonomini M, Valentini G, Sacchi G, Sansoni E, et al. Prevention of peritoneal sclerosis: a new proposal to substitute glucose with carnitine dialysis solution (biocompatibility testing in vitro and in rabbits). Int J Artif Organs 2005; 28:177-87.
7. Suyama K, Kumano K, Sasaki T. Agents preventing decrease in ultrafiltration in a rat model with peritoneal hyperpermeability. Nippon Jinzo Gakkai Shi 1995; 37:491-6.
8. Fracasso A, Baggio B, Ossi E, Del Prete D, Bonfante L, Bazzato G, et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 1999; 33:105-10.
9. Sjoland JA, Smith PR, Jespersen J, Gram J. Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant 2004; 19:1264-8.
10. Pawlaczyk K, Kuzlan-Pawlaczyk M, Anderstam B, Heimburger O, Bergstrom J, Waniewski J, et al. Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis. Nephrol Dial Transplant 2001; 16:669-71.
11. Zareie M, Keuning ED, ter Wee PM, Beelen RH, van den BJ. Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats. Nephrol Dial Transplant 2005; 20:189-93.
12. Rodrigues A, Cabrita A, Maia P, Guimaraes S. Peritoneal rest may successfully recover ultrafiltration in patients who develop peritoneal hyperpermeability with time on continuous ambulatory peritoneal dialysis. Adv Perit Dial 2002; 18:78-80.
13. Sjoland JA, Pedersen RS, Jespersen J, Gram J. Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients. Nephron Clin Pract 2005; 100:c105-10.
14. Nakayama M, Sakai A, Numata M, Hosoya T. Hyper-vascular change and formation of advanced glycation end-products in the peritoneum caused by methylglyoxal and the effect of an anti-oxidant, sodium sulfite. Am J Nephrol 2003; 23:390-4.
15. Labbe P, Pelletier M, Omara FO, Girard D. Functional responses of human neutrophils to sodium sulfite (Na2SO3) in vitro. Hum Exp Toxicol 1998; 17:600-5.
16. Chamulitrat W. Activation of the superoxide-generating NADPH oxidase of intestinal lymphocytes produces highly reactive free radicals from sulfite. Free Radic Biol Med 1999; 27:411-21.
17. Beck-Speier I, Lenz AG, Godleski JJ. Responses of human neutrophils to sulfite. J Toxicol Environ Health 1994; 41:285-97.
18. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
19. Goode NP, Shires M, Crellin DM, Davison AM. Detection of glomerular anionic sites in post-embedded ultra-thin sections using cationic colloidal gold. J Histochem Cytochem 1991; 39:965-72.
20. Henry CB, Duling BR. Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am J Physiol 1999; 277:H508-H514.
21. 2) in human fibroblasts cultures. Glycoconj J 2004; 20:133-41.
22. Slevin M, Kumar S, Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting endothelial cell mitogenic and wound healing responses. J Biol Chem 2002; 227:41046-59.
23. West DC, Kumar S. Hyaluronan and angiogenesis. Ciba Found Symp 1989; 143:187-201.
24. Watanabe M, Nakayasu K, Okisaka S. The effect of hyaluronic acid on proliferation and differentiation of capillary endothelial cells. Nippon Ganka Gakkai Zasshi 1993; 97:1034-9.
25. West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985; 228:1324-6.
26. Kumar S, Ponting J, Rooney P, Kumar P, Pye D, Wang M, eds. Angiogenesis: Molecular Biology and Clinical Applications. New York: Plenum Press; 1998: 219-31.
27. Breborowicz A, Pyda M, Moberly J, Martis L, Oreopoulos D. Effect of hyaluronan-supplemented dialysate on in vitro function of human peritoneal mesothelial cells. Am J Nephrol 2004; 24:316-21.
28. Wang T, Cheng H, Heimburger O, Waniewski J, Bergstrom J, Lindholm B. Hyaluronan prevents the decrease in net fluid removal caused by increased dialysate fill volume. Kidney Int 1998; 53:496-502.
29. Guo QY, Peng WX, Cheng HH, Ye RG, Lindholm B, Wang T. Hyaluronan preserves peritoneal membrane transport properties. Perit Dial Int 2001; 21:136-42.
30. Breborowicz A, Polubinska A, Pawlaczyk K, Kuzlan-Pawlaczyk M, Moberly J, Martis L, et al. Intraperitoneal hyaluronan administration in conscious rats: absorption, metabolism, and effects on peritoneal fluid dynamics. Perit Dial Int 2001; 21:130-5.
31. Pappenheimer JR, Renkin EM, Borrero LM. Filtration, diffusion and molecular sieving through peripheral capillary membranes: a contribution to the pore theory of capillary permeability. Am J Physiol 1951; 167:13-46.
32. Grotte G. Passage of dextran molecules across the blood-lymph barrier. Acta Chir Scand 1956; 1(Suppl 211):84.
33. Rippe B. A three-pore model of peritoneal transport. Perit Dial Int 1993; 13(Suppl 2):S35-8.
34. Moberly JB, Sorkin M, Kucharski A, Ogle K, Mongoven J, Skoufos L, et al. Effects of intraperitoneal hyaluronan on peritoneal fluid and solute transport in peritoneal dialysis patients. Perit Dial Int 2003; 23:63-73.
35. Fracasso A, Baggio B, Masiero M, Bonfante L, Bazzato G, Feriani M, et al. Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients. Perit Dial Int 2003; 23:595-8.
36. Peng H, Cheung AK, Reimer LG, Kamerath CD, Leypoldt JK. Effect of indomethacin on peritoneal protein loss in a rabbit model of peritonitis. Kidney Int 2001; 59:44-51.
37. Zemel D, Struijk DG, Dinkla C, Stolk LM, ten Berge IJ, Krediet RT. Effects of intraperitoneal cyclooxygenase inhibition on inflammatory mediators in dialysate and peritoneal membrane characteristics during peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med 1995; 126:204-15.
38. Douma CE, de Waart DR, Zemel D, Struijk DG, Krediet RT. Prostaglandin inhibition by intraperitoneal indomethacin has no effect on peritoneal permeability during stable CAPD. Nephrol Dial Transplant 2001; 16:803-8.
39. Wang T, Cheng HH, Heimbürger O, Chen C, Bergstrom J, Lindholm B. Intraperitoneal atrial natriuretic peptide increases peritoneal fluid and solute removal. Kidney Int 2001; 60:513-19.
40. Naiki Y, Maeda Y, Matsuo K, Yonekawa S, Sakaguchi M, Iwamoto I, et al. Involvement of TGF-β signal for peritoneal sclerosing in continuous ambulatory peritoneal dialysis. J Nephrol 2003; 16:95-102.
41. Matsuo K, Maeda Y, Naiki Y, Matsuoka T, Tamai Y, Yonekawa S, et al. Possible effects of hepatocyte growth factor for the prevention of peritoneal fibrosis. Nephron Exp Nephrol 2005; 99:e87-94.
42. Kothapalli D, Frazier KS, Welply A, Segarini PR, Grotendorst GR. Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor-dependent signaling pathway. Cell Growth Differ 1997; 8:61-8.
43. Faull RJ. Bad and good growth factors in the peritoneal cavity. Nephrology (Carlton) 2005; 10:234-9.
44. Zarrinkalam KH, Stanley JM, Gray J, Oliver N, Faull RJ. Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients. Kidney Int 2003; 64:331-8.
45. Sakamoto N, Sugimura K, Kawashima H, Tsuchida K, Takemoto Y, Naganuma T, et al. Influence of glucose and inflammatory cytokines on TGF-beta 1 and CTGF mRNA expression in human peritoneal mesothelial cells. Int J Mol Med 2005; 15:907-11.
46. Thaler K, Mack JA, Berho M, Grotendorst G, Wexner SD, Abramson SR. Coincidence of connective tissue growth factor expression with fibrosis and angiogenesis in postoperative peritoneal adhesion formation. Eur Surg Res 2005; 37:235-41.
47. Kim YL, Khanna R, Moore HL, Pecoits R, Kommala DR, Twardowski ZJ, et al. Effects of dialysis solution pH on peritoneal transport of glucose in rats [Abstract]. ASAIO J 1997; 43:80.
48. Mortier S, De Vriese AS, McLoughlin RM, Topley N, Schaub TP, Passlick-Deetjen J, et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003; 14:1296-306.
49. Douvdevani A, Rapoport J, Konforty A, Yulzari R, Moran A, Chamovitz C. Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages. J Am Soc Nephrol 1995; 6:207-13.
50. Liberek T, Topley N, Jorres A. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron 1993; 65:260-5.
51. Yamaji Y, Nakazato Y, Oshima N, Hayashi M, Saruta T. Oxidative stress induced by iron released from transferrin in low pH peritoneal dialysis solution. Nephrol Dial Transplant 2004; 19:2592-7.
52. Zareie M, Keuning ED, ter Wee PM, Schalkwijk CG, Beelen RHJ, Van Den Born J. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH. Nephrol Dial Transplant 2006; 21:208-16.
53. Krack G, Viglino G, Cavalli PL, Gandolfo C, Magliano G, Cantaluppi A, et al. Intraperitoneal administration of phosphatidylcholine improves ultrafiltration in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1992; 12:359-64.
54. Hills BA. Role of surfactant in peritoneal dialysis. Perit Dial Int 2000; 20:503-15.
55. De Vecchi A, Castelnovo C, Guerra L, Scalamogna A. Phosphatidylcholine administration in continuous ambulatory peritoneal dialysis (CAPD) patients with reduced ultrafiltration. Perit Dial Int 1989; 9:207-10.
56. Chan PC, Tam SC, Robinson JD, Yu L, Ip MS, Chan CY, et al. Effect of phosphatidylcholine on ultrafiltration in patients on continuous ambulatory peritoneal dialysis. Nephron 1991; 59:100-3.
57. Mactier R, Khanna R, Twardowski Z, Moore H, Nolph K. Influence of phosphatidylcholine on lymphatic absorption during peritoneal dialysis in the rat. Perit Dial Int 1988; 8:179-86.
58. Struijk D, van Der Reijden H, Krediet R, Koomen G, Arisz L. Effect on phosphatidylcholine on peritoneal transport and lymphatic absorption in a CAPD patient with sclerosing peritonitis. Nephron 1989; 51:577-8.
59. Zareie M, Tangelder GJ, ter Wee PM, Hekking LH, van Lambalgen AA, Keuning ED, et al. Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodelling in a rat model of PD. Nephrol Dial Transplant 2005; 20:2783-92.
60. Lamb E, Cattell WR, Dawnay A. In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 1995; 47:1768-74.
61. Lee EA, Oh JH, Lee HA, Kim SI, Park EW, Park KB, et al. Structural and functional alterations of the peritoneum after prolonged exposure to dialysis solutions: role of aminoguanidine. Perit Dial Int 2001; 21:245-53.
62. Shostak A, Gotloib L. Increased peritoneal permeability to albumin in streptozotocin diabetic rats. Kidney Int 1996; 49:705-14.
63. Miyoshi H, Taguchi T, Sugiura M, Takeuchi M, Yanagisawa K, Watanabe Y, et al. Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. Horm Metab Res 2002; 34:371-7.
64. Brunkhorst R, Mahiout A. Pyruvate neutralizes peritoneal dialysate cytotoxicity: maintained integrity and proliferation of cultured mesothelial cells. Kidney Int 1995; 48:177-81.
65. Amdrae U, Singh J, Ziegler-Shylakakis K. Pyruvate and related α-ketoacids protect mammalian cells in culture against hydrogen peroxide induced cytotoxicity. Toxicol Lett 1985; 28:93-8.
66. Shostak A, Pivnik K, Gotloib L. Cultured rat mesothelial cells generate hydrogen peroxide. A new player in peritoneal defense? J Am Soc Nephrol 1996; 7:2371-8.
67. Shostak A, Gotloib L, Kushnier R, Wajsbrot V. Protective effect of pyruvate upon cultured mesothelial cells exposed to 2mM hydrogen peroxide. Nephron 2000; 84:362-6.
68. Van Westrhenen R, Zweers MM, Kune C, de Waart DR, van der Wal AC, Krediet RT. Pyruvate buffered dialysate fluids induce less peritoneal angiogenesis and fibrosis than conventional solutions? In: van Westrhenen R. Understanding and Preventing the Peritoneal Damage Caused by Conventional Solutions [Thesis]. University of Amsterdam 2005; 77-89.
69. Shostak A, Wajsbrot V, Gotloib L. High glucose accelerates the Life cycle of the in-vivo exposed mesothelium. Kidney Int 2000; 58:2044-52.
70. 2 mediated apoptosis in human neuroblastoma cell line-Sk-N-MC. J Chem Neuroanat 2003; 26:209-18.
71. Rayment NB, Haven AJ, Madden B, Murday A, Trickey R, Shipley M, et al. Myocyte loss in chronic heart failure. J Pathol 1999; 188:213-19.
72. Gotloib L, Fudin R, Yakubovich M, Vienken J. Peritoneal dialysis in refractory end-stage congestive heart failure: a challenge facing a no-win situation. Nephrol Dial Transplant 2005; 20(Suppl 7):vii32-6.
73. Wu YT, Wu ZL, Jiang XF, Li S, Zhou FQ. Pyruvate improves neutrophilic nitric oxide generation in peritoneal dialysis solutions. Artif Organs 2005; 29:976-80.
74. Fukagawa NK, Hercules E, Ajami AM. L-Z [3C] oxothiazolidine-4-carboxylic acid: a probe for precursor mobilization for glutathione synthesis. Am J Physiol Endocrin Metab 2000; 278:E171-E176.
75. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 2000; 47: 457-64.
76. Breborowicz A, Breborowicz M, Oreopoulos DG. Glucose-induced changes in the phenotype of human peritoneal mesothelial cells: effect of L-2-oxothiazolidine carbolic acid. Am J Nephrol 2003; 23:471-6.
77. Gotloib L, Shostak A, Wajsbrot V, Kushnier R. High glucose induces a hypertrophic, senescent mesothelial cell phenotype after long in vivo exposure. Nephron 1999; 82:164-73.
78. Gotloib L, Wajsbrot V, Shostak A. Ecology of the peritoneum: a substantial role for the osmotic agents resulting in apoptosis of mesothelial cells. Contrib Nephrol 2003; 140:10-17.
79. Bladier C, Wolvetang EJ, Hutchinson P, de Haan JB, Kola I. Response of a primary human fibroblast cell line to H2O2: senescence-like growth arrest or apoptosis? Cell Growth Differ 1997; 8:589-98.
80. deBono DP, Yang WD. Exposure to low concentrations of hydrogen peroxide causes delayed endothelial cell death and inhibits proliferation of surviving cells. Atherosclerosis 1995; 114:235-45.
81. Zhao B, Cai J, Boulton M. Expression of placenta growth factor is regulated by both VEGF and hyperglycemia via VEGFR-2. Microvasc Res 2004; 68:239-46.
82. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2005; 290:H560-H576.
83. De la Cruz JP, Gonzalez-Correa JA, Guerrero A, De La Cuesta FS. Pharmacological approach to diabetic retinopathy. Diabetes Metab Res Rev 2004; 20:91-113.
84. Obrosova IG, Minchenko AG, Marinescu V, Fathallah L, Kennedy A, Stockert CM, et al. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin diabetic rats. Diabetologia 2001; 44:1102-10.
85. 2, vascular endothelial growth factor and receptors in the retina of the BB2/Wor diabetic rat. Free Radic Biol Med 2000; 28:91-101.
86. Eckardt H, Ding M, Lind M, Hansen ES, Christensen KS, Hvid I. Recombinant human vascular endothelial growth factor enhances bone healing in an experimental non union model. J Bone Joint Surg Br 2005; 87:1434-8.
87. Tarnavski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005; 50(Suppl 1): S34-53.
88. Chen J, Kasper M, Heck T. Tissue factor as a link between wounding and tissue repair. Diabetes 2005; 54:2143-54.
89. Cianfarani F, Tommasi R, Failla CM, Viviano MT, Annessi G, Papi M, et al. Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed. Br J Dermatol 2006; 154:34-41.
90. Kasama T, Miwa Y, Isozaki T, Odai T, Adachi M, Kunkel SL. Neutrophil-dependent cytokine: potential therapeutic targets in inflammation. Curr Drug Targets Inflamm Allergy 2005; 3:273-9.
91. Reinders ME, Sho M, Izawa A, Wang P, Mukhopadhyay D, Koss KE, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003; 112:1655-65.
92. Wojakowski W, Maslankiewicz K, Ochala A, Wyderka R, Zuk-Popiolek I, Flak Z, et al. The pro- and anti-inflammatory markers in patients with acute myocardial infarction and chronic stable angina. Int J Mol Med 2004; 14:317-22.
93. Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of the acute respiratory distress syndrome. J Pathol 2004; 202:145-56.
94. Al Shabrawey M, Bartoli M, El Remessy AB, Platt DH, Matragoon S, Behzadian MA, et al. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic nephropathy. Am J Pathol 2005; 167:599-607.
95. Milkiewicz M, Ispanovic C, Doyle JL, Haas TL. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol 2006; 38:333-57.
96. Tager M, Domrose U, Landgraf G, Weidhase R, Neumann KH. Prothiols in peritoneal dialysis: cytoprotective and anti-inflammatory properties [Abstract]. J Am Soc Nephrol 2005; 16:110A.
97. Kowluru RA. Diabetic retinopathy: mitochondrial dysfunction and retinal capillary death. Antioxid Redox Signal 2005; 7:1581-7.
98. Prahalathan C, Selvakumar E, Varalakshmi P. Modulatory role of lipoid acid on adriamycin-induced testicular injury. Chem Biol Interact 2006; 160:108-14.
99. Su X, Wang L, Song Y, Bai C. Inhibition of inflammatory response by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. Intensive Care Med 2003; 30:133-40.
100. Park NH, Han ES, Lee CS. The inhibitory effect of ambroxol on respiratory burst, degranulation and cytosolic Ca2+ change in degraded immunoglobulin G activated neutrophils. Pharmacol Toxicol 1999; 84:81-7.
101. Miller FN, Wiegman DL, Joshua IG, Nolph KD, Rubin J. Effects of vasodilators and peritoneal dialysis solution on the microcirculation of the rat cecum. Proc Soc Exp Biol Med 1979; 161:605-8.
102. Kumano K, Go M, Nign H, Sakai T. Effects of vasodilators on peritoneal solute and fluid transport in rat peritoneal dialysis. Adv Perit Dial 1996; 12:27-32.
103. Coronel F, Hortal L, Naranjo P, Cruceyra A, Barrientos A. Captopril, proteinuria and peritoneal protein leakage in diabetic patients. Nephron 1989; 51:443.
104. Ripley EBD, Gehr TWB, Kish CW, Sica DA. Hormonal, blood pressure, and peritoneal transport response to short-term ACE inhibitor. Perit Dial Int 1994; 14:378-83.
105. Duman S, Gunal AI, Sen S, Asci G, Ozkahya M, Terzioglu E, et al. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 2001; 21:219-24.
106. Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N. TGF-beta 1 induced by glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int 2005; 25:483-91.
107. Duman S, Sen S, Duman C, Oreopoulos DG. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs 2005; 28:156-63.
108. Imanishi T, Hano T, Nishio L. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 2005; 23:97-104.
109. Faller B, Lameire N. Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over seven years. Nephrol Dial Transplant 1994; 9:280-6.
110. Krediet RT, Douma CE, van Olden RW, Ho-dac-Pannekeet MM, Struijk DG. Augmenting solute clearance in peritoneal dialysis. Kidney Int 1998; 54:2218-25.
111. Di Paolo N, Sacchi G, Vanni L, Corazzi S, Pallini V, Rossi P, et al. Implant of autologous mesothelial cells in animals and a peritoneal dialysis patient. Int J Artif Organs 1989; 12:485-501.
112. Hekking LHP, Zweers MM, Keuning ED, Driesprong BAJ, De Waart DR, Beelen AHJ, et al. Apparent successful mesothelial cell transplantation hampered by peritoneal activation. Kidney Int 2005; 68:2362-7.
113. Folley-Comer AJ, Herrick SE, Al-Mishlab T, Prele CM, Laurent GJ, Mutsaers SE. Evidence for incorporation of free floating mesothelial cells as a mechanism of serosal healing. J Cell Sci 2002; 115:1383-9.
114. Gotloib L, Wajsbrot V, Shostak A. Icodextrin-induced lipid peroxidation disrupts the mesothelial cell cycle engine. Free Radic Biol Med 2003; 34:419-28.
115. Gotloib L, Wajsbrot V, Cuperman Y, Shostak A. Acute oxidative stress induces peritoneal hyperpermeability, mesothelial loss and fibrosis. J Lab Clin Med 2004; 143:31-40.
116. Gotloib L, Wajsbrot V, Shostak A. Osmotic agents hamper mesothelial cell repopulation as seen in the doughnut in vivo model. Perit Dial Int 2005; 25(Suppl 3):S26-30.
117. Gotloib L, Wajsbrot V, Shostak A. A short review of experimental sclerosis: from mice to men. Int J Artif Organs 2005; 28:97-104.
118. Hoff CM, Shockley TR. Genetic modification of the peritoneal membrane: potential for improving peritoneal dialysis through gene therapy. Semin Dial 1998; 11:218-27.
119. Witowski J, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Jorres A, Lage C, et al. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant 2004; 19:917-24.
120. Mortier S, Lameire NH, De Vriese AS. The effects of peritoneal dialysis solutions on peritoneal host defense. Perit Dial Int 2004; 24:123-38.
121. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Perit Dial Int 2005; 25:248-55.